RA(Regulatory Affairs) 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 서비스별, 카테고리별, 제품 유형별, 기업 규모별, 제품 스테이지별, 적응증별, 최종 용도별, 지역별, 부문 동향(2025-2030년)

Regulatory Affairs Market Growth & Trends:

The global regulatory affairs market size is expected to reach USD 27.18 billion by 2030, expanding at a CAGR of 8.80% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors expected to contribute to the growth of this market include changing regulatory requirements based on business activities and geographies, an increase in clinical trials & drug approvals along with accelerated regulatory approval, and technological advancement in regulatory software. Also, the evolution of personalized medicines, the increasing need for companies to focus on core business activities, and economic and competitive pressures are other factors that are contributing to the growth of the market.

The pharmaceutical and regulatory agencies joined forces to rapidly develop vaccines and medical products required to fight against the COVID-19 infection. The regulatory authorities take numerous precautions to ensure patient and personnel safety during a clinical trial, as well as data integrity and good laboratory practices are maintained. Growth in markets for biosimilars, orphan drugs, personalized medicines, companion diagnostics, and adaptive trial designs is projected to boost the demand for regulatory specialization in these areas. As companies venture into newer fields, the growing need to comply with regulations is boosting the demand for specialized service providers with expertise in regulatory affairs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services.

Several companies are actively involved in collaborations and new product development to gain leadership in the personalized medicine market, indicating a need for supportive regulatory affairs. For instance, in May 2020, Regeneron Pharmaceuticals, Inc. collaborated with Colorado Center for Personalized Medicine to design advancements in personalized medicine and human genetics.

Regulatory Affairs Market Report Highlights:

• The outsourcing segment dominated the market with a share of 59.05% in 2024. The growth of the segment is mainly due to the growing focus of the pharmaceutical and medical device companies to outsource their activities as it allows access to specialized expertise and resources that they may not have in-house.
• The regulatory writing & publishing segment held a significant share of the market in 2024. The growth of the segment is attributed to several pharmaceutical or biopharmaceutical companies reducing costs, prioritizing strategic projects, reducing staff training time, and improving overall efficiency, as well as providing greater flexibility.
• The drugs segment dominated the regulatory affairs market in 2024. The growth of the segment can be attributed to various regulations and related regulatory submissions/documentation at each of the steps involved in the process.
• The oncology segment dominated the market in 2024. The growth of the segment is due to the increasing prevalence of cancer, which requires effective and safe treatment options.
• Clinical studies dominated the market in 2024. The increasing prevalence of chronic diseases coupled with the emergence of new diseases will increase the demand for better treatment options, further growing the number of clinical trials conducted globally to meet the growing needs of the patients.
• The medium company size segment dominated the market in 2024. The growth of the market is mainly due to the strong presence of several mid-sized established firms, mainly which are privately held.
• The pharmaceutical companies segment dominated the market in 2024. The growth of the segment is due to growing research and development activities coupled with an increase in the number of approved pharmaceutical products.
• The regulatory affairs market in Asia Pacific dominated the global industry and accounted for a 38.03% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Information Analysis
  • 1.4.2. Market Formulation & Data Visualization
  • 1.4.3. Data Validation & Publishing
• 1.5. Model Details
  • 1.5.1. Commodity Flow Analysis (Model 1)
  • 1.5.2. Top Down Market Estimation (Model 2)
  • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
  • 1.5.4. Multivariate Analysis (Model 4)
• 1.6. List of Secondary Sources
• 1.7. List of Abbreviations
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Regulatory Affairs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Changing regulatory landscape
    • 3.2.1.2. Entry of companies into the global market
    • 3.2.1.3. Life science companies focusing on their core competencies
    • 3.2.1.4. Economic and competitive pressures
    • 3.2.1.5. Demand for the faster approval process for breakthrough drugs and devices
    • 3.2.1.6. Growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Risk Associated with Data Security
    • 3.2.2.2. Monitoring Issues and Lack of Standardization
• 3.3. Industry Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Regulatory Affairs Market: Services Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Regulatory Affairs Market Services Movement Analysis
• 4.3. Global Regulatory Affairs Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
• 4.4. Regulatory Consulting
  • 4.4.1. Regulatory consulting market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Legal Representation
  • 4.5.1. Legal representation market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Regulatory Writing & Publishing
  • 4.6.1. Regulatory writing & publishing market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.1.1. Writing
      • 4.6.1.1.1. Writing market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.1.2. Publishing
      • 4.6.1.2.1. Publishing market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.7. Product Registration & Clinical Trial Applications
  • 4.7.1. Product registration & clinical trial applications market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.8. Other Services
  • 4.8.1. Other services market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Regulatory Affairs Market: Category Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Regulatory Affairs Market Category Movement Analysis
• 5.3. Global Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
• 5.4. Drugs
  • 5.4.1. Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Innovator
    • 5.4.2.1. Innovator market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2.2. Preclinical
      • 5.4.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2.3. Clinical
      • 5.4.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2.4. Pre-Market Approval (PMA)
      • 5.4.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Generics
    • 5.4.3.1. Generics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3.2. Preclinical
      • 5.4.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3.3. Clinical
      • 5.4.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3.4. Pre-Market Approval (PMA)
      • 5.4.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Biologics
  • 5.5.1. Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Biotech
    • 5.5.2.1. Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.2.2. Preclinical
      • 5.5.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.2.3. Clinical
      • 5.5.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.2.4. Pre-Market Approval (PMA)
      • 5.5.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. ATMP
    • 5.5.3.1. ATMP market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3.2. Preclinical
      • 5.5.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3.3. Clinical
      • 5.5.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3.4. Pre-Market Approval (PMA)
      • 5.5.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Biosimilars
  • 5.6.1. Biosimilars market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.1. Preclinical
      • 5.6.1.1.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.2. Clinical
      • 5.6.1.2.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.1.3. Pre-Market Approval (PMA)
      • 5.6.1.3.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Medical Devices
  • 5.7.1. Medical devices market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.2. Diagnostics
    • 5.7.2.1. Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.2.2. Preclinical
      • 5.7.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.2.3. Clinical
      • 5.7.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.2.4. Pre-Market Approval (PMA)
      • 5.7.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Therapeutics
    • 5.7.3.1. Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.3.2. Preclinical
      • 5.7.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.3.3. Clinical
      • 5.7.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.3.4. Pre-Market Approval (PMA)
      • 5.7.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Regulatory Affairs Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Regulatory Affairs Market Indication Movement Analysis
• 6.3. Global Regulatory Affairs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Neurology
  • 6.5.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Cardiology
  • 6.6.1. Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Immunology
  • 6.7.1. Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regulatory Affairs Market: Product Stage Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Regulatory Affairs Market Product Stage Movement Analysis
• 7.3. Global Regulatory Affairs Market Size & Trend Analysis, by Product Stage, 2018 to 2030 (USD Million)
• 7.4. Preclinical
  • 7.4.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Clinical studies
  • 7.5.1. Clinical studies market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Pre-Market Approval (PMA)
  • 7.6.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Regulatory Affairs Market: Type Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Regulatory Affairs Market Type Movement Analysis
• 8.3. Global Regulatory Affairs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 8.4. In-house
  • 8.4.1. In-house market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Outsourced
  • 8.5.1. Outsourced market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Regulatory Affairs Market: Company Size Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Global Regulatory Affairs Market Company Size Movement Analysis
• 9.3. Global Regulatory Affairs Market Size & Trend Analysis, by Company Size, 2018 to 2030 (USD Million)
• 9.4. Small
  • 9.4.1. Small market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.5. Medium
  • 9.5.1. Medium market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.6. Large
  • 9.6.1. Large market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Regulatory Affairs Market: End-use Estimates & Trend Analysis

• 10.1. Segment Dashboard
• 10.2. Global Regulatory Affairs Market End-use Movement Analysis
• 10.3. Global Regulatory Affairs Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 10.4. Medical Device Companies
  • 10.4.1. Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 10.5. Pharmaceutical Companies
  • 10.5.1. Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 10.6. Biotechnology Companies
  • 10.6.1. Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 11. Regulatory Affairs Market: Regional Estimates & Trend Analysis

• 11.1. Regional Market Share Analysis, 2024 & 2030
• 11.2. Regional Market Dashboard
• 11.3. Market Size & Forecasts Trend Analysis, 2018 to 2030 (USD Million)
• 11.4. North America
  • 11.4.1. North America Market Estimates and Forecasts 2018 to 2030, (USD Million)
  • 11.4.2. U.S.
    • 11.4.2.1. Key country dynamics
    • 11.4.2.2. Competitive scenario
    • 11.4.2.3. Regulatory scenario
    • 11.4.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.4.3. Canada
    • 11.4.3.1. Key country dynamics
    • 11.4.3.2. Competitive scenario
    • 11.4.3.3. Regulatory scenario
    • 11.4.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.4.4. Mexico
    • 11.4.4.1. Key country dynamics
    • 11.4.4.2. Competitive scenario
    • 11.4.4.3. Regulatory scenario
    • 11.4.4.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• 11.5. Europe
  • 11.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 11.5.2. UK
    • 11.5.2.1. Key country dynamics
    • 11.5.2.2. Competitive scenario
    • 11.5.2.3. Regulatory scenario
    • 11.5.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.3. Germany
    • 11.5.3.1. Key country dynamics
    • 11.5.3.2. Competitive scenario
    • 11.5.3.3. Regulatory scenario
    • 11.5.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.4. France
    • 11.5.4.1. Key country dynamics
    • 11.5.4.2. Competitive scenario
    • 11.5.4.3. Regulatory scenario
    • 11.5.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.5. Italy
    • 11.5.5.1. Key country dynamics
    • 11.5.5.2. Competitive scenario
    • 11.5.5.3. Regulatory scenario
    • 11.5.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.6. Spain
    • 11.5.6.1. Key country dynamics
    • 11.5.6.2. Competitive scenario
    • 11.5.6.3. Regulatory scenario
    • 11.5.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.7. Denmark
    • 11.5.7.1. Key country dynamics
    • 11.5.7.2. Competitive scenario
    • 11.5.7.3. Regulatory scenario
    • 11.5.7.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.8. Norway
    • 11.5.8.1. Key country dynamics
    • 11.5.8.2. Competitive scenario
    • 11.5.8.3. Regulatory scenario
    • 11.5.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.9. Netherlands
    • 11.5.9.1. Key country dynamics
    • 11.5.9.2. Competitive scenario
    • 11.5.9.3. Regulatory scenario
    • 11.5.9.4. Netherlands market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.10. Switzerland
    • 11.5.10.1. Key country dynamics
    • 11.5.10.2. Competitive scenario
    • 11.5.10.3. Regulatory scenario
    • 11.5.10.4. Switzerland market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.5.11. Sweden
    • 11.5.11.1. Key country dynamics
    • 11.5.11.2. Competitive scenario
    • 11.5.11.3. Regulatory scenario
    • 11.5.11.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• 11.6. Asia Pacific
  • 11.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 11.6.2. Japan
    • 11.6.2.1. Key country dynamics
    • 11.6.2.2. Competitive scenario
    • 11.6.2.3. Regulatory scenario
    • 11.6.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.3. China
    • 11.6.3.1. Key country dynamics
    • 11.6.3.2. Competitive scenario
    • 11.6.3.3. Regulatory scenario
    • 11.6.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.4. India
    • 11.6.4.1. Key country dynamics
    • 11.6.4.2. Competitive scenario
    • 11.6.4.3. Regulatory scenario
    • 11.6.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.5. Australia
    • 11.6.5.1. Key country dynamics
    • 11.6.5.2. Competitive scenario
    • 11.6.5.3. Regulatory scenario
    • 11.6.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.6. South Korea
    • 11.6.6.1. Key country dynamics
    • 11.6.6.2. Competitive scenario
    • 11.6.6.3. Regulatory scenario
    • 11.6.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.7. Thailand
    • 11.6.7.1. Key country dynamics
    • 11.6.7.2. Competitive scenario
    • 11.6.7.3. Regulatory scenario
    • 11.6.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.8. Indonesia
    • 11.6.8.1. Key country dynamics
    • 11.6.8.2. Competitive scenario
    • 11.6.8.3. Regulatory scenario
    • 11.6.8.4. Indonesia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.9. Malaysia
    • 11.6.9.1. Key country dynamics
    • 11.6.9.2. Competitive scenario
    • 11.6.9.3. Regulatory scenario
    • 11.6.9.4. Malaysia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.10. Singapore
    • 11.6.10.1. Key country dynamics
    • 11.6.10.2. Competitive scenario
    • 11.6.10.3. Regulatory scenario
    • 11.6.10.4. Singapore market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.6.11. Taiwan
    • 11.6.11.1. Key country dynamics
    • 11.6.11.2. Competitive scenario
    • 11.6.11.3. Regulatory scenario
    • 11.6.11.4. Taiwan market estimates and forecasts, 2018 - 2030 (USD Million)
• 11.7. Latin America
  • 11.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 11.7.2. Brazil
    • 11.7.2.1. Key country dynamics
    • 11.7.2.2. Competitive scenario
    • 11.7.2.3. Regulatory scenario
    • 11.7.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.7.3. Argentina
    • 11.7.3.1. Key country dynamics
    • 11.7.3.2. Competitive scenario
    • 11.7.3.3. Regulatory scenario
    • 11.7.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.7.4. Colombia
    • 11.7.4.1. Key country dynamics
    • 11.7.4.2. Competitive scenario
    • 11.7.4.3. Regulatory scenario
    • 11.7.4.4. Colombia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.7.5. Chile
    • 11.7.5.1. Key country dynamics
    • 11.7.5.2. Competitive scenario
    • 11.7.5.3. Regulatory scenario
    • 11.7.5.4. Chile market estimates and forecasts, 2018 - 2030 (USD Million)
• 11.8. MEA
  • 11.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 11.8.2. South Africa
    • 11.8.2.1. Key country dynamics
    • 11.8.2.2. Competitive scenario
    • 11.8.2.3. Regulatory scenario
    • 11.8.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.8.3. Saudi Arabia
    • 11.8.3.1. Key country dynamics
    • 11.8.3.2. Competitive scenario
    • 11.8.3.3. Regulatory scenario
    • 11.8.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.8.4. UAE
    • 11.8.4.1. Key country dynamics
    • 11.8.4.2. Competitive scenario
    • 11.8.4.3. Regulatory scenario
    • 11.8.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.8.5. Egypt
    • 11.8.5.1. Key country dynamics
    • 11.8.5.2. Competitive scenario
    • 11.8.5.3. Regulatory scenario
    • 11.8.5.4. Egypt market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.8.6. Israel
    • 11.8.6.1. Key country dynamics
    • 11.8.6.2. Competitive scenario
    • 11.8.6.3. Regulatory scenario
    • 11.8.6.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)
  • 11.8.7. Kuwait
    • 11.8.7.1. Key country dynamics
    • 11.8.7.2. Competitive scenario
    • 11.8.7.3. Regulatory scenario
    • 11.8.7.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Competition Categorization
  • 12.1.1. Market Leaders
  • 12.1.2. Emerging Players
• 12.2. Company Market Share/Assessment Analysis, 2024
• 12.3. Company Profiles
  • 12.3.1. Accell Clinical Research, LLC
    • 12.3.1.1. Company overview
    • 12.3.1.2. Financial performance
    • 12.3.1.3. Service benchmarking
    • 12.3.1.4. Strategic initiatives
  • 12.3.2. Genpact
    • 12.3.2.1. Company overview
    • 12.3.2.2. Financial performance
    • 12.3.2.3. Service benchmarking
    • 12.3.2.4. Strategic initiatives
  • 12.3.3. Criterium, Inc.
    • 12.3.3.1. Company overview
    • 12.3.3.2. Financial performance
    • 12.3.3.3. Service benchmarking
    • 12.3.3.4. Strategic initiatives
  • 12.3.4. ICON plc
    • 12.3.4.1. Company overview
    • 12.3.4.2. Financial performance
    • 12.3.4.3. Service benchmarking
    • 12.3.4.4. Strategic initiatives
  • 12.3.5. iuvo BioScience, LLC.
    • 12.3.5.1. Company overview
    • 12.3.5.2. Financial performance
    • 12.3.5.3. Service benchmarking
    • 12.3.5.4. Strategic initiatives
  • 12.3.6. WuXi AppTec
    • 12.3.6.1. Company overview
    • 12.3.6.2. Financial performance
    • 12.3.6.3. Service benchmarking
    • 12.3.6.4. Strategic initiatives
  • 12.3.7. Medpace
    • 12.3.7.1. Company overview
    • 12.3.7.2. Financial performance
    • 12.3.7.3. Service benchmarking
    • 12.3.7.4. Strategic initiatives
  • 12.3.8. Charles River Laboratories
    • 12.3.8.1. Company overview
    • 12.3.8.2. Financial performance
    • 12.3.8.3. Service benchmarking
    • 12.3.8.4. Strategic initiatives
  • 12.3.9. Laboratory Corporation of America Holdings
    • 12.3.9.1. Company overview
    • 12.3.9.2. Financial performance
    • 12.3.9.3. Service benchmarking
    • 12.3.9.4. Strategic initiatives
  • 12.3.10. Parexel International (MA) Corporation
    • 12.3.10.1. Company overview
    • 12.3.10.2. Financial performance
    • 12.3.10.3. Service benchmarking
    • 12.3.10.4. Strategic initiatives
  • 12.3.11. Freyr
    • 12.3.11.1. Company overview
    • 12.3.11.2. Financial performance
    • 12.3.11.3. Service benchmarking
    • 12.3.11.4. Strategic initiatives
  • 12.3.12. PHARMALEX GMBH
    • 12.3.12.1. Company overview
    • 12.3.12.2. Financial performance
    • 12.3.12.3. Service benchmarking
    • 12.3.12.4. Strategic initiatives
  • 12.3.13. SSI Strategy LLC
    • 12.3.13.1. Company overview
    • 12.3.13.2. Financial performance
    • 12.3.13.3. Service benchmarking
    • 12.3.13.4. Strategic initiatives
  • 12.3.14. Pharmexon
    • 12.3.14.1. Company overview
    • 12.3.14.2. Financial performance
    • 12.3.14.3. Service benchmarking
    • 12.3.14.4. Strategic initiatives
  • 12.3.15. Qvigilance
    • 12.3.15.1. Company overview
    • 12.3.15.2. Financial performance
    • 12.3.15.3. Service benchmarking
    • 12.3.15.4. Strategic initiatives
  • 12.3.16. BlueReg
    • 12.3.16.1. Company overview
    • 12.3.16.2. Financial performance
    • 12.3.16.3. Service benchmarking
    • 12.3.16.4. Strategic initiatives
  • 12.3.17. Cambridge Regulatory Services
    • 12.3.17.1. Company overview
    • 12.3.17.2. Financial performance
    • 12.3.17.3. Service benchmarking
    • 12.3.17.4. Strategic initiatives
  • 12.3.18. VCLS
    • 12.3.18.1. Company overview
    • 12.3.18.2. Financial performance
    • 12.3.18.3. Service benchmarking
    • 12.3.18.4. Strategic initiatives